Prostate Cancer: New Guidelines Urge Men Over 50 to Get PSA


  • The American Cancer Society (ACS) now recommends prostate-specific antigen (PSA) screening every 2 years starting at age 50 for men at average risk, and annually starting at age 45 for those at higher risk, including Black men and men with a family history of prostate cancer.
  • The updated guidance reflects new evidence that regular PSA screening can reduce the risk of dying from prostate cancer by 13% and help detect potentially aggressive cancers before they spread.
  • If PSA levels are elevated, additional testing, including prostate MRIs and biomarker tests, can help determine whether a biopsy is necessary, potentially reducing unnecessary procedures.

As rates of advanced prostate cancer continue to rise, the American Cancer Society (ACS) has issued new guidelines recommending routine prostate cancer screening for many men starting at age 50.

The updated recommendations, published November 12 in CA: A Cancer Journal for Clinicians, mark a shift from the organization’s previous emphasis on shared decision making about whether to undergo screening.

Advances in MRI technology and biomarker testing may also help doctors determine which men need further testing, potentially reducing unnecessary biopsies and overtreatment.

The ACS last updated its prostate cancer screening guidelines in 2010, when conflicting research findings raised questions about whether the benefits of PSA screening outweighed the potential harms.

At the time, the organization emphasized informed, shared decision making between patients and healthcare professionals.

However, longer-term follow-up studies have since provided stronger evidence of the benefits of early detection, prompting the ACS to conduct a systematic review and update its recommendations.

The authors of the report noted, “In making these recommendations, we recognize that PSA testing is only the first step in a screening cascade that includes secondary testing of men with an elevated PSA level and treatment decisions for men diagnosed with prostate cancer.”

The new guidelines recommend a PSA test every 2 years for men ages 50–69 with an average risk of prostate cancer.

The recommendation for those at high risk is a PSA test every year starting at age 45.

For men ages 70–74, the ACS recommends individualized decision making. If an individual chooses to be screened, the ACS recommends a PSA test every 2 years until the age of 74.

Ramkishen Narayanan, MD, Director of the Center for Urologic Health at The Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center in Burbank, CA, who wasn’t involved in the report, told Healthline that screening shouldn’t automatically be ruled out for men over 75.

“[A] point worth noting is that for men over 75, their PSA history as well as their individual clinical scenarios should be evaluated, and that PSA should not be discouraged in this group of men if their life expectancy and clinical history warrant a PSA check.”

Prostate cancer diagnoses in the United States increased by around 3% per year between 2014 and 2022, according to the ACS.

The rise in diagnoses, particularly advanced-stage prostate cancer, has renewed attention on the importance of regular screening.

“[The] current state of prostate cancer screening guidelines is vague and generalized. This has led to ambiguity, disagreement, and variation of opinion among healthcare providers and institutions in their approach to men’s health,” said S. Adam Ramin, MD, board certified urologist, urologic oncologist, and medical director of Urology Cancer Specialists in Los Angeles, CA, who wasn’t involved in the report.

A 12-year ERSPC follow-up in 2012 also suggested that regular screening was associated with a decrease in metastatic prostate cancer diagnosis, which is another finding that influenced the updated guidance.

“Prostate cancer can take many years, even decades, to become clinically significant, so it takes a long time for us to see the consequences of changes in screening practices,” Taylor Goodstein, MD, assistant professor of urology in the College of Medicine at the University of Cincinnati, who wasn’t involved in the report, told Healthline.

“With longer follow-up from randomized trials, we now have more convincing evidence that PSA screening reduces the risk of dying from prostate cancer,” she said.

“The ACS guidelines are important now because they drive home the most important point that prostate cancer screening saves lives,” said Narayanan.

Goodstein told Healthline that the ways this new guidance can change the outlook for prostate cancer are simple.

“If we screen men, we can catch troublesome cancers early, before they have a chance to spread,” she said.

Goodstein also emphasized how much the evaluation process has changed. In the past, an elevated PSA level often led directly to a biopsy.

Today, doctors generally repeat the PSA test within two weeks to three months to confirm the result. If PSA levels remain elevated, additional testing, including a prostate MRI or validated biomarker test, can help determine whether a biopsy is necessary.

Narayanan told Healthline, “The new guidelines will hopefully remove any confusion about the value of PSA screening and encourage prostate cancer screening as an integral part of a man’s ‘checkup’.”

He added that it is worth noting that the DRE (digital rectal exam) adds little value to the initial prostate cancer screening and is no longer something that men should fear.

“Adoption of this set of specific guidelines standardizes the approach to screening for prostate cancer. It provides a unified effort among all levels of healthcare. It most likely will increase the chances of finding prostate cancer in earlier stages and lead to improved cancer treatment outcomes,” said Ramin.



Source link